Clinical Trials Logo

Acute Lymphoblastic Leukaemia clinical trials

View clinical trials related to Acute Lymphoblastic Leukaemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03593304 Completed - Clinical trials for Acute Lymphoblastic Leukaemia

Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients

Start date: March 29, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study will be conducted to evaluate the effect of vitamin B6 and vitamin B12 in reducing the incidence and severity and delaying the onset of Vincristine Induced neurotoxicity in Acute Lymphobalstic Leukemia (ALL) patient.

NCT ID: NCT01616238 Completed - Clinical trials for Acute Lymphoblastic Leukaemia

A Study for Older Adults With Acute Lymphoblastic Leukaemia

UKALL60+
Start date: December 2012
Phase: Phase 2
Study type: Interventional

The NCRI Adult ALL sub-group propose to collaborate with the Dutch/Belgian group HOVON to carry out a prospective, non randomised multi-arm study (including a choice of regimen intensity) to investigate the safety, tolerability and feasibility of a standardised therapy protocol for patients ≥ 60 years old with de novo ALL. The overall aim is define a basic standard of care upon which trials of novel therapies will be based in future. The design of the study will enable collection of a comprehensive dataset regarding the clinical outcome, Complete Response Rate (CR) and Minimal Residual Disease (MRD) response rates in a previously completely uncharacterised population, thus providing the essential platform for designing future randomised advanced phase studies in which new therapeutic approaches and novel therapies can be prospectively investigated.

NCT ID: NCT01597219 Completed - Clinical trials for Myelodysplastic Syndrome

Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers

UK-Haplo
Start date: March 2013
Phase: Phase 2
Study type: Interventional

This trial investigates stem cell transplants from partially mismatched donors in patients with blood and bone marrow cancers. The trial will test two kinds of transplants - a full intensity transplant using a high dose of radiotherapy and chemotherapy, and a reduced intensity transplant with lower doses of chemotherapy and radiotherapy. Patients will be entered for the treatment pathway that is most appropriate for their level of health and fitness